

# Puma Biotechnology

## Earnings Call

### Commercial Update



February 25, 2021

**nerlynx**<sup>®</sup>  
(neratinib) tablets




## Forward-Looking Safe-Harbor Statement

*This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on our current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on our business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the year ended December 31, 2020, once filed, and subsequent reports. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law.*




# PUMA's Pharmacy and Distributor Network




# ~\$50 Million Net NERLYNX Revenue in Q4'20

Quarterly Net Revenue (in \$MM)



# ~3,600 Ex-factory Bottles were Sold in Q4'20


### Bottles Sold (SP + SD) by Quarter



Includes Commercial SP and SD

# ~38% of Patients in Q4'20 Started at a Reduced Dose

% of patients starting at reduced dose



Reduced dose defined as fewer than 6 pills per day

# Rest of World Partnerships – Timelines

Region	Partner	Regulatory / Launch Milestones
Australia / SE Asia	 Specialised Therapeutics	<ul style="list-style-type: none"> <li>• March 2019 – Approved in Australia</li> <li>• December 2019 – Approved in Singapore</li> <li>• Q2/Q3 2020 – Approved in Brunei, Malaysia, New Zealand</li> </ul>
Israel	 MEDISON Driving Innovative Healthcare	<ul style="list-style-type: none"> <li>• Q1 2020 – Launched</li> <li>• Q3 2020 – Approved in metastatic breast cancer</li> </ul>
Canada	 Knight	<ul style="list-style-type: none"> <li>• July 2019 – Approved</li> <li>• September 2020 – metastatic sNDS accepted by HC</li> </ul>
Latin America	 PINT PHARMA	<ul style="list-style-type: none"> <li>• Q1 2020 – Argentina Launched; <b>mBC approved January 2021</b></li> <li>• Q2 2020 – Approved in Chile</li> <li>• Q3 2020 – Approved in Ecuador</li> <li>• 2021 – Expected approvals in Brazil, Colombia, Mexico, Peru</li> </ul>
Europe Greater China Middle East North and West Africa South Africa Turkey	 Pierre Fabre	<ul style="list-style-type: none"> <li>• Q4 2019 – Germany, UK, Austria Launched</li> <li>• Q1 2020 – Sweden Launched</li> <li>• Q2 2020 – Hong Kong Launched</li> <li>• Q2 2020 – Approved in China</li> <li>• Q3 2020 – Approved in Taiwan</li> <li>• <b>Q4 2020 – Finland / Switzerland Launched</b></li> </ul>
South Korea	 BIINK THERAPEUTICS	<ul style="list-style-type: none"> <li>• October 2020 – NDA Filed</li> </ul>

# Puma Biotechnology

## Earnings Call

### Commercial Update



February 25, 2021

**nerlynx**<sup>®</sup>  
(neratinib) tablets

